| First Author | Lippoldt EK | Year | 2016 |
| Journal | Proc Natl Acad Sci U S A | Volume | 113 |
| Issue | 16 | Pages | 4506-11 |
| PubMed ID | 27051069 | Mgi Jnum | J:232109 |
| Mgi Id | MGI:5776063 | Doi | 10.1073/pnas.1603294113 |
| Citation | Lippoldt EK, et al. (2016) Inflammatory and neuropathic cold allodynia are selectively mediated by the neurotrophic factor receptor GFRalpha3. Proc Natl Acad Sci U S A 113(16):4506-11 |
| abstractText | Tissue injury prompts the release of a number of proalgesic molecules that induce acute and chronic pain by sensitizing pain-sensing neurons (nociceptors) to heat and mechanical stimuli. In contrast, many proalgesics have no effect on cold sensitivity or can inhibit cold-sensitive neurons and diminish cooling-mediated pain relief (analgesia). Nonetheless, cold pain (allodynia) is prevalent in many inflammatory and neuropathic pain settings, with little known of the mechanisms promoting pain vs. those dampening analgesia. Here, we show that cold allodynia induced by inflammation, nerve injury, and chemotherapeutics is abolished in mice lacking the neurotrophic factor receptor glial cell line-derived neurotrophic factor family of receptors-alpha3 (GFRalpha3). Furthermore, established cold allodynia is blocked in animals treated with neutralizing antibodies against the GFRalpha3 ligand, artemin. In contrast, heat and mechanical pain are unchanged, and results show that, in striking contrast to the redundant mechanisms sensitizing other modalities after an insult, cold allodynia is mediated exclusively by a single molecular pathway, suggesting that artemin-GFRalpha3 signaling can be targeted to selectively treat cold pain. |
